Teva (NYSE: TEVA) October weekly call option implied volatility is at 40, October is at 41, November is at 47; compared to its 52-week range of 24 to 61 into Mylan (Nasdaq: MYL) was granted FDA approval of the first generic for Copaxone.

Options Trader Talk

Teva Pharma (TEVA) PT Lowered to $15 at Morgan StanleyOctober 5, 2017 8:58 AM Teva Pharma (TEVA) PT Lowered to $21 at Barclays; Generic Copaxone 40mg Approval 'Will Offset Some Contracting Strategies... Hurt Sentiment'October 4, 2017 12:17 PM Mylan (MYL) PT Raised to $36 at Cowen; Reiterates Market PerformOctober 4, 2017 10:44 AM Mylan (MYL) PT Raised to $45 at BTIG Following Copaxone Generic ApprovalOctober 4, 2017 7:27 AM Mylan's (MYL) Surprise Copaxone Generic Approval 'Quite Negative' for Teva Pharma (TEVA) - MizuhoOctober 4, 2017 7:02 AM Momenta Phama (MNTA) on Watch After Mylan (MYL) Granted FDA Approval of First Generic for CopaxoneOctober 4, 2017 6:42 AM